Stockscreener 앱 받기
21.98
1.25%
0.30
시간 외 거래:
21.81
-0.17
-0.77%
전일 마감가:
$21.68
열려 있는:
$21.82
하루 거래량:
555.03K
Relative Volume:
0.95
시가총액:
$1.44B
수익:
-
순이익/손실:
$-137.95M
주가수익비율:
-8.7132
EPS:
-2.5226
순현금흐름:
$-107.11M
1주 성능:
+9.59%
1개월 성능:
-3.09%
6개월 성능:
+15.53%
1년 성능:
+136.79%
1일 변동 폭
$21.20
$22.50
1주일 범위
$20.12
$22.50
52주 변동 폭
$8.48
$24.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
21.98 | 1.42B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | BofA Securities | Buy |
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
BCAX: Ficera doubled three-year survival and achieved deep, durable responses in HPV-negative head and neck cancer - TradingView
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer - Yahoo Finance
BCAX: Ficerafusp alfa delivers deep, durable responses and doubles three-year survival in HPV-negative head and neck cancer - TradingView
BCAX: FICERA plus pembrolizumab delivers deep, durable responses and extended survival in HPV-negative HNSCC - TradingView
Bicara Therapeutics Reports Positive Three-Year Survival Data for Ficerafusp Alfa Plus Pembrolizumab in 1L R/M HPV-Negative HNSCC - Minichart
Bicara reports three-year survival data for cancer therapy By Investing.com - Investing.com South Africa
Bicara reports three-year survival data for cancer therapy - Investing.com
Bicara Therapeutics Reports Promising Three-Year Follow-Up Data for Ficerafusp Alfa in Combination with Pembrolizumab in HPV-Negative Head and Neck Cancer - Quiver Quantitative
Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC - TradingView
Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options - Stock Titan
Bicara Therapeutics Highlights Momentum in Earnings Call - TipRanks
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum - TipRanks
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock - Investing.com
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock By Investing.com - Investing.com South Africa
Bicara Therapeutics (BCAX) executive sells 12,500 shares under plan - Stock Titan
Bicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Stock Quote - FinancialContent
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet - The Motley Fool
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data - sharewise.com
Number of shareholders of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
BCAX: Ficerafusp alfa delivers unprecedented durability in head and neck cancer, with pivotal data due mid-2025 - TradingView
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Moomoo
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Liquidia Technologies (LQDA) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Biotech firm Bicara heads to Boston and Miami for investor talks - Stock Titan
Bicara Therapeutics’ Acquisition Strategy Poses Operational, Financing, and Shareholder Dilution Risks - TipRanks
Bicara Therapeutics (BCAX) CMO awarded 85,000 options at $22.58 strike - Stock Titan
Bicara Therapeutics (BCAX) CMO reports 175,000-share stock option holdings - Stock Titan
Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley - Moomoo
Bicara Therapeutics Price Target Raised to $37.00/Share From $36.00 by Morgan Stanley - Moomoo
Bicara Therapeutics Inc. reports durable responses for ficerafusp alfa plus pembrolizumab in HPV negative HNSCC - Traders Union
Should Bicara’s Wider Q1 Loss and New Institutional Stakes Shift the BCAX Investment Narrative? - Sahm
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com South Africa
Bicara Q1 2026 slides: FICERA data shines amid earnings miss By Investing.com - Investing.com India
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $46 - Moomoo
Bicara Therapeutics: Runway to Fund Operations Into 1st Half of 2029 >BCAX - Moomoo
Bicara Therapeutics Inc. Common Stock Q1 2026 Earnings Call Summary - Yahoo Finance
Bicara Therapeutics (Nasdaq: BCAX) builds cash to advance cancer drug - Stock Titan
Bicara Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Bicara Therapeutics Inc. Announces Executive Changes - marketscreener.com
Bicara Therapeutics Q1 2026 Loss Widens 40.9% Beyond Estimates - AlphaStreet
Bicara Therapeutics Q1 Loss Widens - Moomoo
Stifel cuts Bicara Therapeutics stock price target on estimates By Investing.com - Investing.com Nigeria
Stifel cuts Bicara Therapeutics stock price target on estimates - Investing.com UK
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer |
May 18 '26 |
Option Exercise |
3.79 |
15,000 |
56,847 |
377,152 |
| Mazumdar Claire | Chief Executive Officer |
May 18 '26 |
Sale |
20.04 |
15,000 |
300,579 |
362,152 |
| Cohlhepp Ryan | President and COO |
May 15 '26 |
Option Exercise |
3.79 |
8,000 |
30,318 |
204,141 |
| Cohlhepp Ryan | President and COO |
May 15 '26 |
Sale |
20.29 |
12,500 |
253,649 |
191,641 |
1.49%
0.12%
자본화:
|
볼륨(24시간):